Stories by Tim Boreham
Experts
CRITERION: Power to the people! Here’s a modern day, hi-tech picks-and-shovels play
Experts
Dr Boreham’s Crucible: EBR’s successful safety test looks like a proper heartstarter
Experts
CRITERION: This ASX biotech is the sole dedicated player in a new $420 billion market
Experts
Dr Boreham’s Crucible: 30 years later, has Cyclopharm finally convinced the US FDA?
Experts
CRITERION: Gimme fuel, gimme fire, gimme … self-serve cappucinos
Experts
CRITERION: Happy to get your hands dirty? Old King Coal’s a profitable old soul
Experts
Dr Boreham’s Crucible: Control Bionics’ world-beating wheelchair is more than a victory for mind over matter
Experts
CRITERION: The ASX cancer fighters with a sting in their treatment tails
Experts
CRITERION: REITs are on sale right now – but are they open for business yet?
Health & Biotech
HealthKick Podcast: Aussie biotech Dimerix expects first data from its DMX200 Phase 3 trial by end of year
Experts